BioCentury
ARTICLE | Clinical News

Cimzia certolizumab pegol: Phase IIIb data

November 15, 2010 8:00 AM UTC

The double-blind, international Phase IIIb REALISTIC trial in 1,063 patients showed that subcutaneous Cimzia met the primary endpoint of significantly improving ACR20 response rate at week 12 vs. vs. ...